Last reviewed · How we verify

NCT06093815

Prospective Study to Assess Tissue Responses After Injection With Biostimulatory Products

Completed NA Last updated 13 December 2024
What this trial tests

NA trial testing Injection in Injection Site Reaction in 20 participants. Completed in 1 November 2024.

Timeline
8 September 2023
Primary endpoint
1 May 2024
1 November 2024

Quick facts

Lead sponsorMerz North America, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment20
Start date8 September 2023
Primary completion1 May 2024
Estimated completion1 November 2024
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Merz North America, Inc. — full company profile →

Who can join

Adults 22 to 65, any sex, with Injection Site Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to identify and assess in vivo tissue responses after injection with various biostimulatory products at various timepoints. The study will also provide tissue specimens which will be used in a subsequent study. Safety endpoint: incidence of adverse events.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Injection

Trials testing the same drug.

Other Merz North America, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06093815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing